Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Main results of pooled HRs in the meta-analysis

From: Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test

Comparisons (miRNA-130 family) Heterogeneity test Summary HR (95% CI) Hypothesis test Studies
Q P I2 (%) Z P
miRNA-130a
 OS
  Total 22.74 0.01 56 1.58 (1.21,2.06) 3.34 < 0.001 11
  Tissue 21.28 0.01 62 1.54 (1.11,2.14) 2.60 0.009 9
  Serum 1.00 0.32 0 1.65 (1.14,2.38) 2.65 0.008 2
  Subgroup differences 0.07 0.79 0     
 Cancer subtypes
  Gastric cancer 1.94 0.38 0 1.81 (1.34,2.45) 3.83 < 0.001 3
  Other cancers 18.30 0.01 62 1.46 (1.01,2.08) 2.11 0.03 8
 DFS
  Total 24.08 < 0.01 79 1.35 (0.72,2.52) 0.93 0.35 6
  Tissue 23.91 < 0.01 83 1.32 (0.52,3.40) 0.58 0.56 5
  Serum 1.38 (0.99,1.91) 0.21 0.83 1
  Subgroup differences 0.01 0.94 0     
miRNA-130b
 OS
  Total 60.10 < 0.01 77 1.95 (1.47,2.59) 4.65 < 0.001 15
  Tissue 44.46 < 0.01 75 2.01 (1.39,2.91) 3.71 < 0.001 12
  Serum 15.50 < 0.01 87 1.96 (1.09,3.54) 2.23 0.03 3
  Subgroup differences 0.01 0.94 0     
 Ethnicity
  Asian 12.15 0.06 51 2.55 (1.77,3.69) 5.00 < 0.001 7
  Caucasian 23.95 < 0.01 71 1.47 (1.08,1.99) 2.45 0.01 8
 Cancer subtypes        
  HCC 10.59 0.01 72 2.43 (1.28,4.63) 8.24 0.004 4
  Other cancers 30.80 < 0.01 74 1.75 (1.30,2.37) 3.67 < 0.001 11
 DFS/PFS
  Total 7.38 0.12 46 1.53 (1.31,1.77) 5.53 < 0.001 5
  Tissue 2.48 0.29 19 1.98 (1.50,2.62) 4.85 < 0.001 3
  Serum 0.03 0.86 0 1.37 (1.15,1.64) 3.46 < 0.001 2
  Subgroup differences 4.87 0.03 79.5     
 Cancer subtypes
  HCC (DFS) 2.48 0.29 19 1.98 (1.50,2.62) 4.85 < 0.001 3
  Other cancers 0.03 0.86 0 1.37 (1.15,1.64) 3.46 < 0.001 2
  1. OS, overall survival; DFS, disease free survival; PFS, progressive free survival; HCC, hepatocellular carcinoma